Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CSF1R | P07333 | 4/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595932 | 0.79 | MARS2 (0.40) | MARS2SMN1; SMN2MAPTLMNAMEN1 | |
| SCHEMBL23419563 | 0.77 | MARS2 (0.46) | MARS2SMN1; SMN2MAPTLMNAMEN1 | |
| SCHEMBL20596490 | 0.76 | MARS2 (0.42) | MARS2SMN1; SMN2MAPTLMNAMEN1 | |
| SCHEMBL20596076 | 0.74 | NOD2 (0.38) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL20595984 | 0.72 | MARS2 (0.75) | MARS2SMN1; SMN2MAPTPOLB | |
| SCHEMBL20595835 | 0.71 | MEN1 (0.38) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL20595923 | 0.69 | CYP1A2 (0.39) | SMN1; SMN2MAPTLMNACSF1RPDGFRB | |
| SCHEMBL20596185 | 0.69 | MARS2 (0.49) | MARS2SMN1; SMN2MAPTPOLB | |
| SCHEMBL20596051 | 0.68 | CA12 (0.37) | SMN1; SMN2MAPTLMNAMEN1KMT2A | |
| SCHEMBL20596534 | 0.68 | LMNA (0.39) | SMN1; SMN2MAPTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885SMN1; SMN2 1129/4885MAPT 3686/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MARS2 5/4885SMN1; SMN2 1329/4885MAPT 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.